Pacific Biosciences Of California (PACB) closed at $2.26 on November 6, 2026, down 7.2% from the previous close, on volume of 9,259,122 shares (30-day average 18,454,735).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Call Spread | 16-Oct : 20-Nov-26 1.5 C | 650 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Thu, 5-Nov 5:50 PM ET)
Barclays Keeps Their Sell Rating on Pacific Biosciences (PACB)
TipRanks (Thu, 5-Nov 3:38 AM ET)
PacBio Reports Third-Quarter Revenue Growth Amid Ongoing Losses
TipRanks (Wed, 4-Nov 4:40 PM ET)
Seeking Alpha News (Wed, 4-Nov 4:18 PM ET)
PacBio Announces Third Quarter 2026 Financial Results
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Cathie Wood's weekly recap: loads TER, AVAV after strong results; books gain in AMD, TSM, LLY
Seeking Alpha News (Mon, 2-Nov 7:05 AM ET)
PacBio Highlights Three November Investor Events, With Two Fireside Chats Set for Webcast
Market Chameleon (Wed, 28-Oct 7:35 AM ET)
PacBio to Participate in Upcoming Investor Conferences
Globe Newswire (Tue, 27-Oct 4:05 PM ET)
Globe Newswire (Mon, 19-Oct 9:05 AM ET)
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Wed, 14-Oct 4:05 PM ET)
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Pacific Biosciences Of California trades on the NASDAQ stock market under the symbol PACB.
As of November 6, 2026, PACB stock price declined to $2.26 with 9,259,122 million shares trading.
PACB has a beta of 0.82, meaning it tends to be less sensitive to market movements. PACB has a correlation of 0.01 to the broad based SPY ETF.
PACB has a market cap of $700.92 million. This is considered a Small Cap stock.
Last quarter Pacific Biosciences Of California reported $41 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.02.
In the last 3 years, PACB traded as high as $10.65 and as low as $.85.
The top ETF exchange traded funds that PACB belongs to (by Net Assets): ARKE, ARKK, ARKG, VTI, IWM.
PACB has outperformed the market in the last year with a price return of +26.7% while the SPY ETF gained +10.8%. PACB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +93.6% and +6.9%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
PACB support price is $2.25 and resistance is $2.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PACB shares will trade within this expected range on the day.
